Brainsway(US:BWAY) Globenewswire·2025-05-13 11:30Core Insights - BrainsWay Ltd. achieved record quarterly sales of $11.5 million in Q1 2025, marking a 27% increase compared to Q1 2024 [1][8] - The company reported an operating profit of $0.6 million, a significant increase of 519% year-over-year, and Adjusted EBITDA rose to $1.3 million, up 81% from the previous year [1][8] - The demand for Deep TMS Systems is strong, with a record shipment of 81 systems in Q1 2025, representing a 42% increase from 57 systems shipped in the same period last year [1][8] Financial Performance - Revenue for Q1 2025 was $11.5 million, up 27% from $9.1 million in Q1 2024 [8][21] - Gross margin remained stable at 75% compared to the prior year [8] - Net profit surged by 897% to $1.1 million in Q1 2025, compared to $0.1 million in Q1 2024 [1][8] Operational Highlights - The company is reiterating its full-year 2025 financial guidance, projecting revenue between $49 million to $51 million, with an operating profit margin of 3% to 4% and Adjusted EBITDA of 11% to 12% [5][8] - BrainsWay's CEO highlighted the growing demand for their technology in treating various mental health disorders, including OCD and anxious depression, and emphasized the importance of relationships with large enterprise customers [5][6] Market Expansion - The company is expanding its global market presence, now operating in key markets including Canada, Asia, India, and Europe [6] - Upcoming catalysts for growth include the next-generation Deep TMS 360™ system and the expansion into new indications supported by additional clinical data [6]